Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat
Data(s) |
01/07/2014
|
---|---|
Resumo |
YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P < 0.0001) and 1.7 times higher than in ET (P = 0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms. |
Identificador | |
Idioma(s) |
eng |
Direitos |
info:eu-repo/semantics/restrictedAccess |
Fonte |
Andersen , C L , Bjørn , M E , McMullin , M F , Harrison , C , Samuelsson , J , Ejerblad , E , Zweegman , S , Fernandes , S , Bareford , D , Knapper , S , Löfvenberg , E , Linder , O , Andreasson , B , Ahlstrand , E , Jensen , M K , Bjerrum , O W , Vestergaard , H , Larsen , H , Klausen , T W , Mourits-Andersen , T , Skov , V , Thomassen , M , Kruse , T , Grønbæk , K & Hasselbalch , H C 2014 , ' Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat ' Leukemia research , vol 38 , no. 7 , pp. 816-821 . DOI: 10.1016/j.leukres.2014.04.002 |
Tipo |
article |